Catalent announces organizational restructuring2 May 2018
Restructuring to support customer demand for fast, integrated biologics development.
Catalent Pharma Solutions has announced key organizational changes within its biologics business to further align its organization with customer demand for integrated and comprehensive, end-to-end biologics solutions. Further underlining Catalent’s commitment to continued growth and investment in biologics, the reorganization follows its 2017 acquisition of Cook Pharmica, and with it the addition of its award-winning 875,000-sq ft facility in Bloomington, Indiana to provide comprehensive biologics development, analytical services, and drug substance and drug product manufacturing.
Tedd Green, former President of Cook Pharmica, becomes Senior Vice President of Catalent Biologics, and will have responsibility for the entire biologics business. He will continue to report to Barry Littlejohns, President, Catalent Biologics and Specialty Drug Delivery, and will also act as a member of Catalent’s Executive Leadership Team. Mr Green will be based at the Bloomington facility.
Mike Riley becomes Vice President and General Manager of Drug Substance and Bioanalytical services for Catalent Biologics. He will lead the company’s biologics manufacturing business, including its state-of-the-art mammalian cell-line engineering and biomanufacturing capabilities, and its broad bioanalytical capabilities based at several sites across Catalent’s global network.
Cory Lewis will take on the new role of Vice President and General Manager of the Catalent Biologics Drug Product business, with a focus on successfully growing the Catalent Biologics drug product offerings both in the US and in Europe.
In a further move, Ryan Hawkins has been appointed as General Manager of the Bloomington site, having been instrumental to its success through his contributions and leadership over the last 10 years.
With the $950 million acquisition of Cook Pharmica, in October 2017, Catalent further strengthened its position as a leader in integrated biologics development, clinical and commercial-scale manufacturing and finished product supply. The additions of this first-class team and unparalleled facilities have brought deep expertise in liquid and lyophilized sterile formulation and fill-finish across vials, prefilled syringes, auto-injectors, cartridges, and safety devices, and 2,500L biomanufacturing capacity to augment Catalent’s existing biologics infrastructure. With this additional capacity and expertise, Catalent can now provide a single, trusted partner to accelerate all aspects of biologic drug development.
New portable and ready-to-use upper respiratory drug delivery solution
11 Oct 2018
PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.Read more
CPhI Worldwide announces the winners of the 15th Pharma Awards
10 Oct 2018
17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Micro-Sphere increases capsule filling capacity
8 Oct 2018
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.Read more
Symbiosis secures FDA viral vector process approval
5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New horizontal flow wrapping machine for hermetic packages
3 Oct 2018
Greater product protection thanks to reliable sealing technologies.Read more
Movement on the market reflected at CPhI Worldwide 2018
3 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.Read more
Niche CDMO confirms spray drying for highly potent drugs
1 Oct 2018
Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.Read more
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
1 Oct 2018
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation